



Nelson Chao, MD, MBA

The Global Cancer Challenge: What can we do?

1. Defining the aggregate problems to be addressed.
2. Global health requires systems solutions to bring together twinning projects, government organizations and individual efforts into a sustainable critical mass.
3. Oncology care is essential and can also develop alternative technologies for treatment and networking.
4. Qualified people- recruiting, retaining and sustaining
5. Who benefits from addressing this hard problem?
6. Translating intention into action. Capacity, capability, credibility – sustainable system that can expand geometrically


Global Health: Oncology

- Just the plain facts:
 - Of the 7 million cancer deaths, 70% occur in LMIC
 - By 2030, LMIC will bear the brunt of 27 million new cancer cases and 17 million cancer deaths and...
 - 80% of disability adjusted years of life lost to cancer
 - Huge and unperceived costs of inaction

Defining the Problem:

WHO Global Burden of Disease

http://www.who.int/healthinfo/global_burden_disease/projections/en/index.html






Figure Ratio of mortality to incidence in a specific year by cancer type and country income Case fatality (calculated by approximation from the ratio of mortality to incidence in a specific year) is much lower in high-income countries than in lo...

Paul Farmer , Julio Frenk , Felicia M Knaul , Lawrence N Shulman , George Alleyne , Lance Armstrong , Rifat Atun ...

Expansion of cancer care and control in countries of low and middle income: a call to action


The Lancet Volume 376, Issue 9747 2010 1186 - 1193

[http://dx.doi.org/10.1016/S0140-6736\(10\)61152-X](http://dx.doi.org/10.1016/S0140-6736(10)61152-X)

Defining the problem for example


ACCESS TO RADIOTHERAPY:

Radiotherapy is an essential part of the treatment of cancer



The state of global health in 2014

J. Sepulveda and C. Murray, Sci 345:1275, 2014



YLL- years of life lost DAH- Development assistance for health	Low income		Lower middle income		Upper middle income	
	YLL	DAH	YLL	DAH	YLL	DAH
HIV/AIDS	7.6%	41.6%	3.7%	32.0%	4.8%	41.1%
Malaria	11.2%	14.3%	4.8%	9.6%	0.0%	2.2%
Tuberculosis	3.1%	3.3%	3.5%	6.6%	1.0%	7.0%
Maternal, newborn, and child health	37.8%	17.1%	32.1%	23.7%	8.1%	7.0%
Noncommunicable diseases	20.7%	0.2%	34.0%	1.0%	65.3%	2.9%
Other	19.7%	23.5%	21.9%	27.1%	20.8%	39.8%

“Need” →
“Investment” →


After the windfall:

Plateauing budgets for global health sharpen the focus on what really works

M. Enserink, Science 354:1258, 2014

The end of the surge


Aid for global health, by channel



Source: Institute for Health Metrics and Evaluation

Skewed funding For NCDs

The diseases that cause the highest burden—expressed in disability-adjusted life years, or DALYs—don't get most of the international largesse. In 2010, HIV/AIDS



- Malaria
- HIV/AIDS
- Tuberculosis
- Maternal, newborn, and child health
- Noncommunicable diseases
- Other

Source: Institute for Health Metrics and Evaluation

Need for rapid scale up of cancer treatment

- Humanitarian need: ~4 million deaths yearly in LMIC could be averted with early detection and treatment, especially in children.
- Need for palliation since many are not curable but could be adequately palliated.
- Prevention strategies, community engagement
- Treatment services: pathology, radiology, pharmacy, chemotherapy, surgery, radiation therapy – many could be tied to existing efforts in infectious diseases or other subspecialties.
- Terrible inequities: almost 80% of the disability-adjusted life-years lost worldwide to cancer are in LMIC but have only about 5% or less in resources.

Preventable Cancers:

- Tobacco cessation: lung, head and neck, bladder cancers
- HPV: cervical and head and neck cancers
- Hepatitis infections: hepatocellular carcinomas


Early Detection and treatment

- Cervical cancer
- Breast cancer
- Colorectal cancer
- Chronic myelogenous leukemia

Curable with systemic treatment

- Burkitt's lymphoma
- Diffuse large cell lymphoma
- Hodgkin's lymphoma
- Testicular cancer
- Acute lymphoblastic leukemia
- Soft tissue sarcoma
- Osteosarcoma
- Chronic myelogenous leukemia

What would be needed?



It is feasible and effective

- Much can be done without the latest and most expensive technologies
- Low cost services can be beneficial even in wealthy countries
- The HIV and TB experience demonstrates that complex diseases can be cared for in LMIC
- Bulk purchases can bring prices down dramatically
- Effective diagnosis and treatment can be delivered even in rural areas.

Global Cancer Care – Low hanging fruit?

Telepathology

Virtual tumor board

Case based seminars

Visiting faculty

Visiting students


Private-public partnerships

Twinning

...

Duke's Approach

- Emphasis on Selected Demonstration Projects
 - Leading with care: Bugando Cancer Center
 - Leading with education: Tata Medical Center training: South-south exchange
 - Leading with research: Barretos Cancer Center
- Plan “Diagonal” Health Care Systems
- Connecting to Established Infrastructure



Progress

1. Full time faculty (Dr. Kristin Schroeder lives and works in Bugando – currently 6 months each year)
2. Adam Olson as a Global Oncology fellow
3. Duke “team” set up and in place (research coordinator, tumor registry, program manager, patient navigator)
4. Supporting partially training for a pediatric oncologist in Italy
5. Planning for a national pediatric tumor network



- 1. Pediatric outcomes:
 - standardized protocols, started a patient navigator system to try to reduce treatment abandonment
 - completed historical data extraction for chart review
 - Poster Abstracts: Pediatric Academic Society 2016; Societe International Oncologie Pediatrique (SIOP 2015 (Cape town), accepted abstract for 2016 as well); CUGH 2016 (San Francisco) ; IPOS/APOA 2016(Calabar, Nigeria)
 - Oral presentation at SDG3 (Emory, 2016); GHOS 2016 (mwanza, TZ) - Mentored Research : Kathryn McHenry (summer research award, Amherst Undergraduate; Fatima Alvi summer research award, Wash University MSII; Jessica McDade (Duke University MS IV)
- 2. Registry:
 - awarded DCI pilot grant 2014 (co-investigator)
 - completed 1st year of registry, enrolled 1,700 patients
 - Accepted publication: Zullig LL, Schroeder K et al. Validation and quality assessment of Kilimanjaro Cancer Registry. JGO 2016
 - submitted P20 (with UCSF, OCRI, etc) --> scored but not awarded, in resubmission
- 3. lymphadenopathy among HIV infected patients
 - Award: DCI pilot grant 2015 (co-PI), CFAR no cost extension for 2015 (PI)
- 4. Burkitt Lymphoma
 - submitted P01 (co-investigator, Ann Moorman PI)
 - Submitted P30 supplement (Co-PI) - awarded
- 5. AMC (AIDS Malignancy Consortium)
 - application to AMC to be clinical trial site, accepted as provisional site
- 6. Palliative Care
 - Mentored Research: Emily Esmaili MD, MS (Duke Masters in Bioethics and Science Policy, thesis work product, Palliative care beliefs among oncology staff and parents of children with cancer at Bugando Cancer Centre)



Progress

1. Full time trainee Eli Mkwizu in Tata Medical Center learning and being treated as a registrar, highly rated by the medical director
2. Six oncology nurses are due to arrive in September to spend 6 weeks in training in the DCI





Progress

1. Full time trainee Dr. Laura Musselwhite spent one year as a global health fellow conducting research in cervical cancer.

This effort has resulted in:

- a. Three abstracts that have been presented
- b. Two manuscripts in preparation
- c. A Gates Grand Challenges Exploration grant to this team for a urine cervical cancer screening tool.
- d. R-01 submission on cervical cancer screening



2. Nimmi Ramanujam research in cervical cancer to be expanded to Barretos (and to Tanzania [KCMC] in addition to sites in Peru, Kenya and Zambia.

3. The third biannual Duke Global Cancer Symposium to be held in Barretos in 2017

Progress

- China efforts:
 - Held interest group meeting March 2016 and second planned for October 2016
 - Multiple groups have individual efforts on going
 - Duke leads with Beijing military hospital on an international phase III trial of microtransplantation for acute leukemia
 - Interest in Kushan for possible smoking prevention studies

Unique Role for Duke: People, Expertise, Programs, and Vision

- Duke is well-positioned to partner with developing world stakeholders to investigate how to build cancer care health systems
- Resulting analytic model could be applied to any NCD and any country
- Cross-disciplinary training of physicians and others in global health is unique to the US and specifically to Duke; gives us the skills to catalyze development efforts for global health systems

Potential Contributors From Duke Programs and Initiatives

- Duke Cancer Institute: clinical expertise and health services, population science, and outcomes group
- Duke Global Health Institute: Regional expertise, epidemiologists, economists, Global Health Major, MSc Students, Doctoral Scholars
- Bass Connections
- School of Medicine, School of Nursing, Sanford School of Public Policy, Fuqua School of Business, Nicholas School of the Environment
- Social Entrepreneurship and Global Health (eg. CASE, SEAD, and IPIHD)

Ingredients of a “Duke” Approach

Answering Key Questions in Global Oncology

- Leverage Technical Expertise
- Support Regional Partners

Research on How to Expand Impact/Sustainability

- Scaling successful innovations to more rapidly build cancer care systems in different settings
- Integrate with Duke’s programmatic strengths in social entrepreneurship and scaling social impact



